Company / Accounts Receivable
Veracyte, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$44.7M
FY2025
5-year range
$40.4M / $46.5M
FY2021-FY2025
Trend
-4.0%
vs FY2024
Sector context
#118 of 143
Health Care
What the data says
Veracyte, Inc.'s accounts receivable of $45M is lower than 83% of companies in the Health Care sector (FY2025). Accounts Receivable has fluctuated over the past 10 years, ranging from $9M in FY2016 to $47M in FY2024.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +19.3%.
Improved from $40M to $45M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +0.5%
- 5-Year CAGR
- +19.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 143This company $44.7M Sector average $1.3B
▼
-96.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.3%, indicating consistent growth.
- In FY2025, accounts receivable decreased 4.0% year-over-year.
- Ranks #118 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.7M | -4.0% |
| FY2024 | $46.5M | +15.2% |
| FY2023 | $40.4M | -8.3% |
| FY2022 | $44.0M | +6.2% |
| FY2021 | $41.5M | +124.6% |
| FY2020 | $18.5M | -4.5% |
| FY2019 | $19.3M | +46.8% |
| FY2018 | $13.2M | +3.6% |
| FY2017 | $12.7M | +45.2% |
| FY2016 | $8.8M | +150.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026